Prophylactic effect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution

Journal of Pharmacological Sciences

Volumn 106, Issue 3, 2008, Pages 469-477

  Suzuki, Takahiro ^a   Yoshida, Norimasa ^a   Nakabe, Nami ^a   Isozaki, Yutaka ^a   Kajikawa, Hirokazu ^a   Takagi, Tomohisa ^a   Handa, Osamu ^a   Kokura, Satoshi ^a   Ichikawa, Hiroshi ^a   Naito, Yuji ^a   Matsui, Hirofumi ^b   Yoshikawa, Toshikazu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Aspirin; Gastric mucosal injury; Rebamipide; Tight junction; Zonula occludens (ZO) 1

Indexed keywords

ACETYLSALICYLIC ACID; DEXTRAN; ISOTHIOCYANIC ACID; MYELOPEROXIDASE; PROTEIN ZO1; REBAMIPIDE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PERMEABILITY BARRIER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; STOMACH EPITHELIUM; STOMACH EROSION; STOMACH MUCOSA; STOMACH MUCOSA INJURY; TIGHT JUNCTION;

EID: 41549127509     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0071422     Document Type: Article

References (68)

1. [No authors listed]. Collaborative overview of randomized trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ. 1994;308:81-106.
2. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomized trials of antiplatelet therapy for preven tion of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
3. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353:2373-2383.
4. Sorensen HT, Mellemkjaer L, Blot WJ, Nielsen GL, Steffensen FH, McLaughlin JK, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol. 2000;95:2218-2224.
5. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321:1183-1187.
6. Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001;52:563-571.
7. Lee M, Feldman M. Age-related reductions in gastric mucosal prostaglandin levels increase susceptibility to aspirin-induced injury in rats. Gastroenterology. 1994;107:1746-1750.
8. Konturek SJ, Piastucki I, Brozowski T, Radecki T, Dembinskakiec A, Zmuda A, et al. Role of prostaglandins in the formation of aspirin-induced gastric ulcers. Gastroenterology. 1981;80:4-9.
9. Ligumsky M, Golanska E, Hansen DG, Kauffman GL. Aspirin can inhibit gastric mucosal cyclooxygenase without causing lesions in rats. Gastroenterology. 1983;84:756-761.
10. Naito Y, Yoshikawa T, Yagi N, Matsuyama K, Yoshida N, Seto K, et al. Effects of polaprezinc on lipid peroxidation, neutrophil accumulation, and TNF-alpha expression in rats with aspirin-induced gastric mucosal injury. Dig Dis Sci. 2001;46:845-851.
11. Fries JF. NSAID gastropathy: Epidemiology. J Musculoskel Med. 1991;8:21-28.
12. Takeuchi K, Ueshima K, Hironaka Y, Fujioka Y, Matsumoto J, Okabe S. Oxygen free radicals and lipid peroxidation in the pathogenesis of gastric mucosal lesions induced by indomethacin in rats. Digestion. 1991;49:175-184.
13. Wallece JL, Keenan CM, Granger DN. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol. 1990;259:G462-G467.
14. Yoshida N, Yoshikawa T, Nakamura Y, Arai M, Matsuyama K, Iinuma S, et al. Role of neutrophil-mediated inflammation in aspirin-induced gastric mucosal injury. Dig Dis Sci. 1995;40:2300-2304.
15. Hawkey CJ. Non-steroidal anti-inflammatory drug gastropathy: causes and treatment. Scand J Gastroenterol. 1996;220:124-127.
16. McCarthy DM. Mechanisms of mucosal injury and healing: the role of non-steroidal anti-inflammatory drugs. Scand J Gastroenterol. 1995;208:24-29.
17. Meddings JB, Gibbons I. Discrimination of site-specific alterations in gastrointestinal permeability in the rat. Gastroenterology. 1998;114:83-92.
18. Cereijido M, Shoshani L, Contreras RG. Molecular physiology and pathophysiology of tight junctions. I. Biogenesis of tight junctions and epithelial polarity. Am J Physiol Gastrointest Liver Physiol. 2000;279:G477-G482.
19. Gonzalez-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight junction proteins. Prog Biophys Mol Biol. 2003;81:1-44.
20. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell. 1996;84:345-357.
21. Aijaz S, Balda MS, Matter K. Tight junctions: molecular architecture and function. Int Rev Cytol. 2006;248:261-298.
22. Mitic LL, Anderson JM. Molecular architecture of tight junctions. Annu Rev Physiol. 1998;60:121-142.
23. Yap AS, Brieher WM, Gumbiner BM. Molecular and functional analysis of cadherin-based adherens junctions. Annu Rev Cell Dev Biol. 1997;13:119-146.
24. Heiskala M, Peterson PA, Yang Y. The roles of claudin superfamily proteins in paracellular transport. Traffic. 2001;2:93-98.
25. Harhaj NS, Antonetti DA. Regulation of tight junctions and loss of barrier function in pathophysiology. Int J Biochem Cell Biol. 2004;36:1206-1237.
26. Meyer TN, Schwesinger C, Denker BM. Zonula occludens-1 is a scaffolding protein for signaling molecules. Galpha (12) directly binds to the Src homology 3 domain and regulates paracellular permeability in epithelial cells. J Biol Chem. 2002;277:24855-24858.
27. Sawada N, Murata M, Kikuchi K, Osanai M, Tobioka H, Kojima T, et al. Tight junctions and human diseases. Med Electron Microsc. 2003;36:147-156.
28. Arakawa T, Higuchi K, Fujiwara Y, Watanabe T, Tominaga K, Sasaki E, et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50:S3-S11.
29. Arakawa T, Kobayashi K, Yoshikawa T, Tarnawski A. Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing. Dig Dis Sci. 1998;43:5S-13S.
30. Kleine A, Kluge S, Peskar BM. Stimulation of prostaglandin biosynthesis mediates gastroprotective effect of rebamipide in rats. Dig Dis Sci. 1993;38:1441-1449.
31. Sun WH, Tsuji S, Tsujii M, Gunawan ES, Kawai N, Kimura A, et al. Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent. J Pharmacol Exp Ther. 2000;295:447-452.
32. Murata H, Yabe Y, Tsuji S, Tsujii M, Fu HY, Asahi K, et al. Gastro-protective agent rebamipide induces cyclooxygenease-2 (COX-2) in gastric epithelial cells. Dig Dis Sci. 2005;50:S70-S75.
33. Suetsugu H, Ishihara S, Moriyama N, Kazumori H, Adachi K, Fukuda R, et al. Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa. J Lab Clin Med. 2000;136:50-57.
34. Tarnawski A, Arakawa T, Kobayashi K. Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci. 1998;43:90S-98S.
35. Tarnawski AS, Chai J, Pai R, Chiou SK. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci. 2004;49:202-209.
36. Udagawa A, Shiota G, Ichiba M, Murawaki Y. Effect of rebamipide on acetic acid-induced gastric ulcer in rats: involvement of hepatocyte growth factor. Scand J Gastroenterol. 2003;38:141-146.
37. Ishihara K, Komuro Y, Nishiyama N, Yamasaki K, Hotta K. Effect of rebamipide on mucus secretion by endogenous prostaglandin-independent mechanism in rat gastric mucosa. Arzneimittelforschung. 1992;42:1462-1466.
38. Naito Y, Yoshikawa T, Tanigawa T. Hydroxyl radicals scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radical Biol Med. 1995;18:117-123.
39. Shimoyama T, Fukuda S, Liu Q, Fukuda Y, Nakaji S, Sugawara K. Characteristics of attenuating effects of rebamipide, an anti-ulcer agent, on oxidative burst of human neutrophils. J Pharmacol Sci. 2003 Feb;91:153-157.
40. Yoshikawa T, Naito Y, Tanigawa T, Kondo M. Free radical scavenging activity of the novel anti-ulcer agent rebamipide studied by electron spin resonance. Arzneimittelforschung. 1993;43:363-366.
41. Yoshida N, Yoshikawa T, Iinuma S, Arai M, Takenaka S, Sakamoto K, et al. Rebamipide protects against activation of neutrophils by Helicobacter pylori. Dig Dis Sci. 1996;41:1139-1144.
42. Murakami K, Okajima K, Harada N, Isobe H, Okabe H. Rebamipide prevents indomethacin-induced gastric mucosal lesion formation by inhibiting activation of neutrophils in rats. Dig Dis Sci. 1998;43:139S-142S.
43. Masamune A, Yoshida M, Sakai Y, Shimosegawa T. Rebamipide inhibits ceramide-induced interleukin-8 production in Kato III human gastric cancer cells. J Pharmacol Exp Ther. 2001;298:485-492.
44. Damman HG. Effect of rebamipide on aspirin-induced gastric damage: A case control study. Eur J Gastroenterol Hepatol. 1994;6:911-915.
45. Naito Y, Yoshikawa T, Iinuma S. Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study. Dig Dis Sci. 1998;43:S83-S89.
46. Yamasaki K, Kanbe T, Chijiwa T, Ishiyama H, Morita S. Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. Eur J Pharmacol. 1987;142:23-29.
47. Yoshikawa T, Naito Y, Nakamura S, Nishimura S, Kaneko T, Iinuma S, et al. Effect of rebamipide on lipid peroxidation and gastric mucosal injury induced by indomethacin in rats. Arzneimittelforschung. 1993;43:1327-1330.
48. Joh T, Takezono Y, Oshima T, Sasaki M, Seno K, Yokoyama Y, et al. The protective effect of rebamipide on paracellular permeability of rat gastric epithelial cells. Aliment Pharmacol Ther. 2003;18:133-138.
49. Naito Y, Kajikawa H, Mizushima K, Shimozawa M, Kuroda M, Katada K, et al. Rebamipide, a gastro-protective drug, inhibits indomethacin-induced apoptosis in cultured rat gastric mucosal cells: association with the inhibition of growth arrest and DNA damage-induced 45 alpha expression. Dig Dis Sci. 2005;50:S104-S112.
50. Nagano Y, Matsui H, Muramatsu M, Shimokawa O, Shibahara T, Yanaka A, et al. Rebamipide significantly inhibits indomethacin-induced mitochondrial damage, lipid peroxidation, and apoptosis in gastric epithelial RGM-1 cells. Dig Dis Sci. 2005;50:S76-S83.
51. Hiratsuka T, Futagami S, Shindo T, Hamamoto T, Ueki N, Suzuki K, et al. Rebamipide reduces indomethacin-induced gastric injury in mice via down-regulation of ICAM-1 expression. Dig Dis Sci. 2005;50:S84-S89.
52. Ohkawa H, Ohnishi N, Yagi K. Assay for lipid peroxidates for animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351-358.
53. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
54. Grisham MB, Hernandez LA, Granger DN. Xanthine oxidase and neutrophil infiltration in intestinal ischemia. Am J Physiol. 1986;252:G567-G574.
55. Kobayashi I, Kawano S, Tsuji S, Matsui H, Nakama A, Sawaoka H, et al. RGM 1, a cell line derived from normal gastric mucosa of rat. In Vitro Cell Dev Biol Anim. 1996;32:259-261.
56. Yeomans ND, Lanas AI, Talley NJ, Thomson AB, Daneshjoo R, Eriksson B, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005;22:795-801.
57. Goldstein JL, Lowry SC, Lanza FL, Schwartz HI, Dodge WE. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2- selective inhibitor. Aliment Pharmacol Ther. 2006;23:1489-1498.
58. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110:255-258.
59. Venerito M, Treiber G, Wex T, Kuester D, Roessner A, Di Mario F, et al. Effects of low-dose aspirin on gastric erosions, cyclooxygenase expression and mucosal prostaglandin-E2 do not depend on Helicobacter pylori infection. Aliment Pharmacol Ther. 2006;23:1225-1233.
60. Legen I, Kristl A. Ketoprofen-induced intestinal permeability changes studied in side-by-side diffusion cells. J Pharm Pharmacol. 2002;54:1419-1422.
61. Davies NM. Review article: non-steroidal anti-inflammatory drug-induced gastrointestinal permeability. Aliment Pharmacol Ther. 1998;12:303-320.
62. Meyer RA, McGinley D, Posalaky Z. Effects of aspirin on tight junction structure of the canine gastric mucosa. Gastroenterology. 1986;91:351-359.
63. Sheth P, Seth A, Thangavel M, Basuroy S, Rao RK. Epidermal growth factor prevents acetaldehyde-induced paracellular permeability in Caco-2 cell monolayer. Alcohol Clin Exp Res. 2004;28:797-804.
64. Sappington PL, Han X, Yang R, Delude RL, Fink MP. Ethyl pyruvate ameliorates intestinal epithelial barrier dysfunction in endotoxemic mice and immunostimulated caco-2 enterocytic monolayers. J Pharmacol Exp Ther. 2003;304:464-476.
65. Montalto M, Maggiano N, Ricci R, Curigliano V, Santoro L, Di Nicuolo F, et al. Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells. Digestion. 2004;69:225-228.
66. Nakashima T, Maeda T, Nagamoto H, Kumakura T, Takai M, Mori T. Rebamipide enema is effective for treatment of experimental dextran sulfate sodium induced colitis in rats. Dig Dis Sci. 2005;50:S124-S131.
67. Blikslager AT, Roberts MC, Rhoads JM, Argenzio RA. Prostaglandins I2 and E2 have a synergistic role in rescuing epithelial barrier function in porcine ileum. J Clin Invest. 1997;100:1928-1933.
68. Suetsugu H, Ishihara S, Moriyama N, Kazumori H, Adachi K, Fukuda R, et al. Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa. J Lab Clin Med. 2000;136:50-57.